Summit Therapeutics Plc Stock Analysis
| SMMT Stock | USD 20.24 0.45 2.17% |
Summit Therapeutics PLC is overvalued with Real Value of 17.17 and Target Price of 32.15. The main objective of Summit Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Summit Therapeutics PLC is worth, separate from its market price. There are two main types of Summit Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Summit Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Summit Therapeutics is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Summit Stock trading window is adjusted to America/New York timezone.
Summit |
Summit Stock Analysis Notes
About 84.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.31. Summit Therapeutics PLC had not issued any dividends in recent years. The entity had 1:1 split on the 21st of September 2020. Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. The company was founded in 2003 and is based in Cambridge, Massachusetts. Summit Therapeu operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 105 people. To find out more about Summit Therapeutics PLC contact Robert Duggan at 305-203-2034 or learn more at https://www.summittxinc.com.Summit Therapeutics PLC Investment Alerts
| Summit Therapeutics had very high historical volatility over the last 90 days | |
| Net Loss for the year was (221.31 M) with profit before overhead, payroll, taxes, and interest of 705 K. | |
| Summit Therapeutics PLC currently holds about 121.97 M in cash with (142.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.61. | |
| Roughly 84.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from businesswire.com: Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 |
Summit Therapeutics PLC Upcoming and Recent Events
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Summit Largest EPS Surprises
Earnings surprises can significantly impact Summit Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-10-30 | 2024-09-30 | -0.07 | -0.08 | -0.01 | 14 | ||
2024-08-06 | 2024-06-30 | -0.06 | -0.09 | -0.03 | 50 | ||
2019-06-26 | 2019-03-31 | -0.16 | -0.2 | -0.04 | 25 |
Summit Therapeutics Environmental, Social, and Governance (ESG) Scores
Summit Therapeutics' ESG score is a quantitative measure that evaluates Summit Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Summit Therapeutics' operations that may have significant financial implications and affect Summit Therapeutics' stock price as well as guide investors towards more socially responsible investments.
Summit Therapeutics Thematic Classifications
In addition to having Summit Therapeutics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
 | Health ManagementHealthcare providers, hospitals | |
 | BiotechBiotechnology and pharmaceuticals production and services | |
 | Israel Wall StreetLarge Israel companies traded on major USA exchanges |
Summit Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2024-12-31 | 1.2 M | Rock Springs Capital Management Lp | 2024-12-31 | 1.1 M | Goldman Sachs Group Inc | 2024-12-31 | 910 K | Northern Trust Corp | 2024-12-31 | 871.4 K | Candriam Luxembourg S.c.a. | 2024-12-31 | 842.6 K | Td Asset Management Inc | 2024-12-31 | 838 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 561 K | Twin Tree Management, Lp | 2024-12-31 | 495.8 K | Bnp Paribas Arbitrage, Sa | 2024-12-31 | 493.2 K | Baker Bros Advisors Lp | 2024-12-31 | 24.4 M | Vanguard Group Inc | 2024-12-31 | 11.7 M |
Summit Market Capitalization
The company currently falls under 'Large-Cap' category with a current market capitalization of 15.26 B.Summit Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.51) | (0.54) | |
| Return On Assets | (0.51) | (0.53) | |
| Return On Equity | (0.57) | (0.60) |
Management Efficiency
Summit Therapeutics PLC has return on total asset (ROA) of (0.4131) % which means that it has lost $0.4131 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.949) %, meaning that it created substantial loss on money invested by shareholders. Summit Therapeutics' management efficiency ratios could be used to measure how well Summit Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to gain to 0.0008 in 2025, whereas Return On Tangible Assets are likely to drop (0.54) in 2025. At this time, Summit Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 457.3 M in 2025, whereas Non Current Liabilities Total is likely to drop slightly above 4.8 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.54 | 0.61 | |
| Net Current Asset Value | 128.1 K | 113.8 K | |
| Tangible Asset Value | 47 M | 49.4 M | |
| Tangible Book Value Per Share | 0.54 | 0.43 | |
| Enterprise Value Over EBITDA | 40.7 K | 42.7 K | |
| Price Book Value Ratio | 32.99 | 31.34 | |
| Enterprise Value Multiple | 40.7 K | 42.7 K | |
| Price Fair Value | 32.99 | 31.34 | |
| Enterprise Value | 12.7 B | 13.4 B |
Summit Therapeutics PLC has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Technical Drivers
As of the 26th of March, Summit Therapeutics has the Semi Deviation of 4.99, coefficient of variation of 1975.43, and Risk Adjusted Performance of 0.0512. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Summit Therapeutics PLC, as well as the relationship between them.Summit Therapeutics PLC Price Movement Analysis
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Summit Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Summit Therapeutics PLC. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Summit Therapeutics PLC Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Summit Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Summit Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Summit Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Summit Therapeutics Outstanding Bonds
Summit Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Summit Therapeutics PLC uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Summit bonds can be classified according to their maturity, which is the date when Summit Therapeutics PLC has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Summit Therapeutics Predictive Daily Indicators
Summit Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Summit Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 76206.63 | |||
| Daily Balance Of Power | (0.48) | |||
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 20.17 | |||
| Day Typical Price | 20.19 | |||
| Price Action Indicator | (0.15) | |||
| Period Momentum Indicator | (0.45) | |||
| Relative Strength Index | 51.14 |
Summit Therapeutics Corporate Filings
8K | 24th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 24th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 14th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 13th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 6th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 30th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 15th of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 3rd of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Summit Therapeutics Forecast Models
Summit Therapeutics' time-series forecasting models are one of many Summit Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Summit Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Summit Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Summit Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Summit shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Summit Therapeutics. By using and applying Summit Stock analysis, traders can create a robust methodology for identifying Summit entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (128.64) | (122.21) | |
| Operating Profit Margin | (117.71) | (111.82) | |
| Net Loss | (121.45) | (115.38) | |
| Gross Profit Margin | (2.95) | (2.81) |
Current Summit Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Summit analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Summit analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 32.15 | Strong Buy | 7 | Odds |
Most Summit analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Summit stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Summit Therapeutics PLC, talking to its executives and customers, or listening to Summit conference calls.
Summit Stock Analysis Indicators
Summit Therapeutics PLC stock analysis indicators help investors evaluate how Summit Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Summit Therapeutics shares will generate the highest return on investment. By understating and applying Summit Therapeutics stock analysis, traders can identify Summit Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 71.4 M | |
| Common Stock Shares Outstanding | 718.5 M | |
| Total Stockholder Equity | 388.7 M | |
| Property Plant And Equipment Net | 7.4 M | |
| Cash And Short Term Investments | 412.3 M | |
| Cash | 104.9 M | |
| Accounts Payable | 4.6 M | |
| Net Debt | -97.6 M | |
| 50 Day M A | 20.2939 | |
| Total Current Liabilities | 41.7 M | |
| Other Operating Expenses | 226.3 M | |
| Non Current Assets Total | 11.8 M | |
| Non Currrent Assets Other | 2.5 M | |
| Stock Based Compensation | 51 M |
Additional Tools for Summit Stock Analysis
When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.